- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06495996
El estudio Protrieve PROTECTOR (PROTECTOR)
PROTECTOR: Evaluación de la seguridad y eficacia de la vaina Protrieve para prevenir la embolia pulmonar intraprocedimiento clínicamente significativa al proporcionar protección embólica en la VCI durante los procedimientos de trombectomía para tratar la TVP
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The primary study objective is to evaluate the safety and effectiveness of the Protrieve Sheath in preventing clinically significant intraprocedural pulmonary embolism by providing embolic protection in the IVC during thrombectomy procedures to treat DVT.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Newport Beach, California, Estados Unidos, 92663
- Hoag Hospital
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510
- Yale University
-
-
Florida
-
Miami, Florida, Estados Unidos, 33176
- Baptist Health South Florida
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46204
- IU Health Methodist Hospital
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21218
- MedStar Union Memorial Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Beth Israel Deaconess Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89102
- University Medical Center Southern Nevada
-
-
New Jersey
-
Englewood, New Jersey, Estados Unidos, 07631
- Englewood Hospital
-
-
New York
-
New York, New York, Estados Unidos, 10016
- NYU Langone Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15212
- Allegheny General Hospital
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Vanderbilt University Medical Center
-
-
Texas
-
Galveston, Texas, Estados Unidos, 77555
- University of Texas Medical Branch
-
Houston, Texas, Estados Unidos, 77030
- University of Texas MD Anderson Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26506
- West Virginia University Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Age ≥ 18 years
-
Planned intervention for DVT presenting with one or more of the following characteristics indicative of elevated risk for PE:
- Bilateral iliofemoral DVT
- Clot extending into or located in the IVC
- In-stent thrombosis
- Presence of thrombosed IVC filter
- Other features that the investigator deems put the subject at elevated risk for thromboembolism
-
Willing and able to provide informed consent
Exclusion Criteria:
- Current symptomatic PE
- Known anatomic inability to place Protrieve device via jugular vein access site
- Presence of clot extending to the IVC-Right Atrial junction or in the SVC
- Subject is pregnant
- Severe allergy to iodinated contrast agents that cannot be mitigated
- INR > 1.7 if not currently on anticoagulation therapy, platelets < 50,000/μl which cannot be corrected prior to enrollment, or Hemoglobin < 8.0 g/dL
- Severe renal impairment in patients who are not yet on dialysis that in the Investigator's discretion would pose risk to the patient with the use of marketed contrast agents
- Subject is participating in another study that may interfere with this study
- Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject
- Subject has previously completed or withdrawn from this study
- Limb-threatening circulatory compromise (e.g., phlegmasia)
- Uncontrolled severe hypertension on repeated readings (systolic > 180mmHg or diastolic > 105mmHg)
- Severe allergy, hypersensitivity to, or thrombocytopenia from heparin
- Inability to provide therapeutic anticoagulation per Investigator discretion
- Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period
- Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Protrieve Sheath
The Protrieve Sheath is intended for embolic protection in the inferior vena cava (IVC) to prevent clinically significant intraprocedural pulmonary embolism during mechanical thrombectomy procedures in patients with high risk of embolization. |
Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Primary Effectiveness Measure:
Periodo de tiempo: 24 Hours (+-12 Hours)
|
a. Clinically significant PE |
24 Hours (+-12 Hours)
|
|
Primary Safety Measure:
Periodo de tiempo: 24 Hours (+-12 Hours)
|
|
24 Hours (+-12 Hours)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Capture of Thromboembolic Material
Periodo de tiempo: 24 Hours (+-12 Hours)
|
a. Capture and removal of thromboembolic material in the Protrieve funnel, as assessed by proportion of study cases where any material was either entrapped in the funnel or removed via Protrieve |
24 Hours (+-12 Hours)
|
|
Device Success
Periodo de tiempo: 24 Hours (+-12 Hours)
|
b. Device success, defined as successful delivery, deployment, and retrieval of the Protrieve device without complications |
24 Hours (+-12 Hours)
|
|
Venous Access Routes
Periodo de tiempo: 24 Hours (+-12 Hours)
|
c. Thrombectomy via supplementary venous access routes |
24 Hours (+-12 Hours)
|
|
Estimated Percentage of the Protrieve Funnel Obstructed
Periodo de tiempo: 24 Hours (+-12 Hours)
|
d. Estimated percentage of the Protrieve funnel obstructed by clot, as observed by visual inspection or imaging |
24 Hours (+-12 Hours)
|
|
Blood Transfusions
Periodo de tiempo: 24 Hours (+-12 Hours)
|
e. Blood transfusions associated with Protrieve Sheath access site bleeding |
24 Hours (+-12 Hours)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Ripal Gandhi, MD, Baptist Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 23-003
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .